"Paroxysmal Nocturnal Hemoglobinuria (PNH)" is a rare, acquired disease that leads to the destruction of red blood cells. This process is called "hemolysis". When it becomes intense, it's referred to as a "breakthrough hemolysis". During clinical trials, it's important to define and understand breakthrough hemolysis in order to manage it properly in clinical practice.
Determining 'breakthrough hemolysis' involves monitoring patients closely during clinical trials. Symptoms can include fatigue, difficulty breathing, dark urine and jaundice. It is also measured using laboratory tests that detect levels of hemoglobin in the urine and serum lactate dehydrogenase in the blood.
In a clinical setting, managing PNH and breakthrough hemolysis mainly revolves around reducing hemolysis and alleviating symptoms. This could involve treatments such as blood transfusions or medications like eculizumab, which prevents the breakdown of red blood cells.
Further studies via clinical trials may help refine the definition and understanding of breakthrough hemolysis, leading to improved management strategies in clinical practice. |
求助已关闭
30